These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 25764690)

  • 1. [Direct-acting antiviral-resistant variant].
    Imamura M; Chayama K
    Nihon Rinsho; 2015 Feb; 73(2):322-6. PubMed ID: 25764690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Asunaprevir (BMS-650032) for the treatment of hepatitis C virus.
    Akamatsu N; Sugawara Y; Kokudo N
    Expert Rev Anti Infect Ther; 2015; 13(11):1307-17. PubMed ID: 26414905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.
    Suzuki F; Sezaki H; Akuta N; Suzuki Y; Seko Y; Kawamura Y; Hosaka T; Kobayashi M; Saito S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Watahiki S; Miyakawa Y; Kumada H
    J Clin Virol; 2012 Aug; 54(4):352-4. PubMed ID: 22658798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options.
    Suzuki Y; Ikeda K; Suzuki F; Toyota J; Karino Y; Chayama K; Kawakami Y; Ishikawa H; Watanabe H; Hu W; Eley T; McPhee F; Hughes E; Kumada H
    J Hepatol; 2013 Apr; 58(4):655-62. PubMed ID: 23183526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
    Everson GT; Sims KD; Rodriguez-Torres M; Hézode C; Lawitz E; Bourlière M; Loustaud-Ratti V; Rustgi V; Schwartz H; Tatum H; Marcellin P; Pol S; Thuluvath PJ; Eley T; Wang X; Huang SP; McPhee F; Wind-Rotolo M; Chung E; Pasquinelli C; Grasela DM; Gardiner DF
    Gastroenterology; 2014 Feb; 146(2):420-9. PubMed ID: 24184132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A profiling study of a newly developed HCVcc strain PR63cc's sensitivity to direct-acting antivirals.
    Tao W; Gan T; Lu J; Zhong J
    Antiviral Res; 2017 Mar; 139():18-24. PubMed ID: 28025084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Importance of HCV genotype 1 subtypes for drug resistance and response to therapy.
    Wyles DL; Gutierrez JA
    J Viral Hepat; 2014 Apr; 21(4):229-40. PubMed ID: 24597691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from
    Sahuc ME; Sahli R; Rivière C; Pène V; Lavie M; Vandeputte A; Brodin P; Rosenberg AR; Dubuisson J; Ksouri R; Rouillé Y; Sahpaz S; Séron K
    J Virol; 2019 May; 93(10):. PubMed ID: 30842319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C virus resistance to protease inhibitors.
    Halfon P; Locarnini S
    J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protease inhibitor resistance mutations in untreated Brazilian patients infected with HCV: novel insights about targeted genotyping approaches.
    de Carvalho IM; Alves R; de Souza PA; da Silva EF; Mazo D; Carrilho FJ; Queiroz AT; Pessoa MG
    J Med Virol; 2014 Oct; 86(10):1714-21. PubMed ID: 25042789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The practical management of chronic hepatitis C infection in Japan - dual therapy of daclatasvir + asunaprevir.
    Hayes CN; Imamura M; Chayama K
    Expert Rev Gastroenterol Hepatol; 2017 Feb; 11(2):103-113. PubMed ID: 27936974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy.
    Chayama K; Hayes CN
    Viruses; 2015 Oct; 7(10):5328-42. PubMed ID: 26473914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protease Inhibitor Resistance Remains Even After Mutant Strains Become Undetectable by Deep Sequencing.
    Kan H; Imamura M; Uchida T; Hiraga N; Hayes CN; Tsuge M; Abe H; Aikata H; Makokha GN; Chowdhury S; Miki D; Ochi H; Ishida Y; Tateno C; Chayama K
    J Infect Dis; 2016 Dec; 214(11):1687-1694. PubMed ID: 27651415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
    Halfon P; Sarrazin C
    Liver Int; 2012 Feb; 32 Suppl 1():79-87. PubMed ID: 22212577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice.
    Vercauteren K; Brown RJ; Mesalam AA; Doerrbecker J; Bhuju S; Geffers R; Van Den Eede N; McClure CP; Troise F; Verhoye L; Baumert T; Farhoudi A; Cortese R; Ball JK; Leroux-Roels G; Pietschmann T; Nicosia A; Meuleman P
    Gut; 2016 Dec; 65(12):2029-2034. PubMed ID: 26306759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NS3 genetic variability in HCV genotype-1b isolates from liver specimens and blood samples of treatment-naive patients with chronic hepatitis C.
    Maimone S; Musolino C; Squadrito G; Raffa G; Pollicino T; Raimondo G
    Antivir Ther; 2013; 18(1):131-4. PubMed ID: 23547300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
    Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
    J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 96-well based analysis of replicon elimination with the HCV NS5A replication complex inhibitor daclatasvir.
    O'Boyle DR; Nower PT; Sun JH; Fridell R; Wang C; Valera L; Gao M
    J Virol Methods; 2013 Oct; 193(1):68-76. PubMed ID: 23684844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beclabuvir for the treatment of hepatitis C.
    Gentile I; Zappulo E; Buonomo AR; Maraolo AE; Borgia G
    Expert Opin Investig Drugs; 2015; 24(8):1111-21. PubMed ID: 26156630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drugs in development for chronic hepatitis C: a promising future.
    Pockros PJ
    Expert Opin Biol Ther; 2011 Dec; 11(12):1611-22. PubMed ID: 21995412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.